Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Innovative algorithms and IT platform to support clinical trials

WIN 2019 Symposium

23 - 24 Jun 2019

Published: 10 Jul 2019

Views: 765

Rating:

Save

Dr Eitan Rubin - Ben-Gurion University of the Negev, Beersheeba, Israel

Dr Eitan Rubin speaks to ecancer at the WIN 2019 Symposium in Paris about IT platforms that support clinical trials and the innovative algorithms involved.

He explains that the algorithm was developed from scratch and after they were unable to find suitable software on the market, built their own.

Dr Rubin discusses the cost of clinical trials and believes there has to be a more sustainable way in order to be able to run many trials.

Related Videos

Providing equitable cancer care globally

Prof Pat Price - Imperial College London, London, UK

Providing equitable cancer care globally ( Prof Pat Price - Imperial College London, London, UK )

ASCO's strategic plan for cancer care in LMICs

Dr Lynn Schuchter - President, American Society of Clinical Oncology (ASCO), USA

ASCO's strategic plan for cancer care in LMICs ( Dr Lynn Schuchter - President, American Society of Clinical Oncology (ASCO), USA )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Introducing oncology to undergraduate medical and allied health sciences students

Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India

Introducing oncology to undergraduate medical and allied health sciences students ( Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for September 8-14, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 8-14, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer